Test Document | OncLive

NCCN Clinical Practice Guidelines in Oncology Guidelines: Breast cancer. February 7, 2023. Accessed February 14, 2023. http://www.nccn.org Updated NCCN Guidelines recognize MammaPrint UltraLow Risk result, highlighting its clinical utility for women with early-stage breast cancer who can safely forgo toxic treatments with excellent survival rates. Agendia. News release. February 13, 2023. Accessed February 14, 2023. http://agendia.com Lopes Cardozo JMN, Drukker CA, Rutgers EJT, et al. Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial. J Clin Oncol. 2022;40(12):1335-1345. doi:10.1200/JCO.21.02019 Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261